| Date Filed | Type | Description |
| 08/23/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/11/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Quarterly results |
| 07/28/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/20/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 07/19/2023 |
8-K
| Quarterly results |
| 07/19/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/10/2023 |
SC 13G/A
| ARK Investment Management LLC reports a 10.5% stake in Quantum-Si Inc. |
| 06/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/16/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"GUILFORD, Conn. -- -- May 11, 2023 -- Quantum-Si Incorporated , The Protein Sequencing Company TM , today announced financial results for the first quarter ended March 31, 2023. Recent Highlights ● Revenue was $254,000 on orders of $449,000 in the first quarter of 2023. ● Gross margin was 48.8% in the first quarter of 2023. ● Appointed Jeff Keyes as Chief Financial Officer effective May 15, 2023. ● Strengthened commercial, operations, and development teams with several key executive appointments to help advance commercialization operations. ● Attended Association of Biomolecular Resource Facilities Annual Meeting and exhibited four new application notes. 2023 Financial Outlook ● The Company expects non-GAAP operating expense growth to be approximately fl..." |
|
| 05/02/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/29/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/29/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/17/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/15/2023 |
8-K
| Other Events Interactive Data |
| 03/13/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/06/2023 |
8-K
| Quarterly results |
| 03/02/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/10/2023 |
SC 13G/A
| ARK Investment Management LLC reports a 9.9% stake in Quantum-Si Inc. |
| 02/03/2023 |
SC 13G
| BlackRock Inc. reports a 5.4% stake in Quantum-Si Inc |
| 01/30/2023 |
8-K
| Cost Associated with Exit or Disposal Activities Interactive Data |
| 01/12/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 01/09/2023 |
8-K
| Quarterly results |
| 12/20/2022 |
8-K
| Quarterly results |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/07/2022 |
8-K
| Quarterly results |
| 10/04/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"GUILFORD, Conn. -- -- Oct. 4, 2022 -- Quantum-Si Incorporated , a life sciences company commercializing the first next-generation single-molecule protein sequencing platform, today announced the appointment of Jeff Hawkins as Chief Executive Officer. Mr. Hawkins will succeed Dr. Jonathan Rothberg, Founder and Executive Chairman of Quantum-Si, who has also been serving as Interim Chief Executive Officer, and lead the next phase of growth as the Company prepares to launch the Platinum™ instrument, which will be the industry’s first system to enable next generation, single-molecule protein sequencing. This appointment is effective October 10, 2022. “I’m thrilled to welcome Jeff to Quantum-Si. He is a proven business leader and life sciences inventor with decades of experience driving co..." |
|
| 08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/08/2022 |
8-K
| Quarterly results |
| 07/20/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
|